Access cutting-edge b acute lymphoblastic leukemia treatment through this clinical trial at a research site in Anchorage. Study-provided care at no cost to qualified participants.
Access b acute lymphoblastic leukemia specialists in Anchorage at no cost
This study follows strict safety protocols and ethical guidelines
All study-related b acute lymphoblastic leukemia treatment provided free
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
Sponsor: Children's Oncology Group
Check if you qualify for this b acute lymphoblastic leukemia clinical trial in Anchorage, AK
If you're searching for b acute lymphoblastic leukemia treatment options in Anchorage, AK, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Anchorage research site is actively enrolling participants for this clinical trial. You'll receive care from experienced b acute lymphoblastic leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.